ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference Press release LEIDEN, The Netherlands, June 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 04, 2018
ProQR to Present at the Annual Piper Jaffray Healthcare Conference Press release LEIDEN, the Netherlands, Nov. November 21, 2017
ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference Press release LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. October 24, 2017
ProQR to Present at the Chardan Inaugural Gene Therapy Conference Press release LEIDEN, the Netherlands, Oct. 06, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. October 06, 2017
ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis Press release Key updates September 25, 2017
ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial Press release Key Updates August 29, 2017
ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference Press release LEIDEN, The Netherlands, June 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 13, 2017
ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU Press release Key Updates April 03, 2017
ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer Press release LEIDEN, the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr. March 27, 2017